Postoperative Continuous Infusion of Local Anesthesia in Hand-Assisted Retroperitoneoscopic Living Donor Nephrectomy

Abstract Introduction Postoperative pain management in living kidney donor nephrectomy plays a key role in donor comfort and is important for the further acceptance of living kidney donation in times of organ shortage. Standard pain treatment (SPT) based on opioids is limited due to related side eff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2016-07, Vol.48 (6), p.1940-1943
Hauptverfasser: Wahba, R, Kleinert, R, Hellmich, M, Kurschat, C, Heiermann, N, Dieplinger, G, Löser, J, Stippel, D.L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Introduction Postoperative pain management in living kidney donor nephrectomy plays a key role in donor comfort and is important for the further acceptance of living kidney donation in times of organ shortage. Standard pain treatment (SPT) based on opioids is limited due to related side effects. Continuous infusion of local anesthesia (CILA) into the operative field is a promising alternative. The aim of this study was to evaluate whether CILA could reduce the dose of opioids in living kidney donors operated with hand-assisted retroperitoneoscopic donor nephrectomy (HARP). Methods An observational study on 30 living donors was performed. The primary outcome was the difference of morphine equivalents (MEQ) administered between CILA and SPT. Results On day 0 and 1, living donors with CILA received significant less MEQ compared to the SPT group, although on day 1 this effect was not statistically significant (day 0: 6.3 mg, interquartile range [IR] 4.2–11.2 vs 16.8 mg, IR 10.5–22.1, P  = .009; day 1: 5.25 mg, IR 2.1–13.3 vs 13.3 mg, IR 6.7–23.8, P  = .150). On days 2 and 3 there was no difference (day 2: 13.3 mg, IR 0.0–20.0 vs 13.3 mg, IR 6.7–13.3, P  = .708; day 3: 13.3 mg, IR 0.0–26.7 vs 13.3 mg, IR 6.7–20, P  = .825). Overall (days 0 to3) MEQ was also less for CILA without reaching statistical significance (39.6 mg, IR 10.9–70.5 vs 59.6 mg, IR 42.4–72.9, P  = .187). Conclusions CILA seems to be an effective instrument for donor pain management in the first 24 hours after HARP. Its effect abates by 48 hours after surgery, especially if highly potent nonopioids are given.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2016.03.053